Immunotherapy drug eliminates aggressive cancers
A Phase I clinical trial of CD40 agonist antibody 2141-V11 has shown positive results, with six patients seeing their tumours shrink.
CD40 is a cell surface receptor and member of the tumour necrosis factor (TNF) receptor superfamily, proteins that are largely expressed by immune cells.
When triggered, CD40 prompts the rest of immune system to spring into action, promoting anti-tumour immunity and developing tumour-specific T cell responses.
However, CD40 agonist antibodies cause serious adverse reactions even at a low dose. In 2018, researchers at Rockefeller University in New York engineered an enhanced CD40 agonist antibody and injected it directly into tumours to improve its safety and efficacy.
“Seeing these significant shrinkages and even complete remission in such a small subset of patients is quite remarkable,” said first author Juan Osorio, a visiting assistant professor in Ravetch’s Leonard Wagner Laboratory of Molecular Genetics and Immunology and a medical oncologist at Memorial Sloan Kettering Cancer Center.
Induced immune response
Notably, the effect wasn’t limited to tumours that were injected with the drug; tumours elsewhere in the body either got smaller or were destroyed by immune cells.
The trial included 12 patients with melanoma, renal cell carcinoma, and different types of breast cancer. None suffered serious side effects. Six experienced systemic tumour reduction, of which two had a complete response.
“The melanoma patient had dozens of metastatic tumours on her leg and foot, and we injected just one tumour up on her thigh,” Ravetch said. “After multiple injections of that one tumour, all the other tumours disappeared. The same thing happened in the patient with metastatic breast cancer, who also had tumours in her skin, liver, and lung. And even though we only injected the skin tumour, we saw all the tumours disappear.”
The Ravetch lab is now collaborating with researchers at Memorial Sloan Kettering and Duke University on Phase I or II studies in specific cancers, including bladder cancer, prostate cancer, and glioblastoma.
It is hoped that these studies will help to explain why some patients respond to 2141-V11 and others do not.
Diana Turner, Senior Digital Content Editor, DDW
